David R. Langley
53Patents
12h-index
90Co-inventors
87Inventor score
Filing activity: Dec 2, 1988 → Apr 20, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7659270B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 55 | Active |
| US7704992B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 47 | Active |
| US7745636B2 | Hepatitis C virus inhibitors | Human Necessities | 43 | Active |
| US7741347B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 42 | Active |
| US8303944B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 34 | Active |
| US7759495B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 32 | Active |
| US5478854A | Deoxy taxols | Electricity | 28 | Expired |
| US9308236B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | Emerging Cross-Sectional Technologies | 24 | Active |
| US8147818B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 18 | Active |
| US8574563B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 16 | Active |
| US7534792B2 | Pyrrolotriazine kinase inhibitors | Emerging Cross-Sectional Technologies | 15 | Active |
| US9879046B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | Emerging Cross-Sectional Technologies | 13 | Active |
| US4965348A | Dimeric epipodophyllotoxin glucoside derivatives | Human Necessities | 11 | Expired |
| US9850225B2 | Compounds useful as immunomodulators | Emerging Cross-Sectional Technologies | 11 | Active |
| US8492553B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 11 | Active |
| US5395849A | Hybrid antitumor compounds containing a cyclic enediyne and a DNA-binder | Chemistry; Metallurgy | 10 | Expired |
| US8642025B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 9 | Active |
| US9850283B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | Physics | 9 | Active |
| US9856292B2 | Immunomodulators | Emerging Cross-Sectional Technologies | 8 | Active |
| US4935504A | Epipodophyllotoxin glucoside 4'-acyl derivatives | Chemistry; Metallurgy | 8 | Expired |
| US10143746B2 | Immunomodulators | Human Necessities | 8 | Active |
| US8288562B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 8 | Active |
| US10538555B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | Emerging Cross-Sectional Technologies | 7 | Active |
| US10144706B2 | Compounds useful as immunomodulators | Chemistry; Metallurgy | 7 | Active |
| US9006235B2 | Inhibitors of human immunodeficiency virus replication | Chemistry; Metallurgy | 7 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.